Dr. Rizvi on Nivolumab Plus Erlotinib in Patients with EGFR MT NSCLC
June 1st 2014
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response with plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).